Recursion Pharmaceuticals, Inc. Stock Price, News & Analysis

Recursion (NASDAQ: RXRX) has launched the Phase 2/3 POPLAR-NF2 clinical trial for REC-2282, targeting NF2-mutated meningiomas, a condition affecting approximately 33,000 patients annually. The trial, which is randomized and placebo-controlled, expects to enroll around 90 participants, assessing REC-2282's safety and efficacy. This compound has received both Fast Track and Orphan Drug designations from the FDA and the European Commission, positioning it as a potential first-in-class treatment for these debilitating tumors.

Recursion (NASDAQ: RXRX), a biotechnology firm focused on drug discovery, announced its engagement in three upcoming investor conferences. These include the Jefferies Healthcare Conference from June 8 to June 10, 2022, the Goldman Sachs Annual Global Healthcare Conference from June 13 to June 16, 2022, and Morgan Stanley's Putting the Tech in Biotech Conference on June 28, 2022. The company utilizes advanced machine-learning algorithms to enhance drug discovery through its proprietary Recursion Operating System, expanding its extensive biological and chemical datasets.

Recursion (Nasdaq: RXRX) announced significant advancements in its clinical trials and financial results for Q1 2022. The company initiated dosing in its Phase 2 trial for cerebral cavernous malformation (CCM) and plans to start a Phase 2/3 trial for NF2-mutated meningiomas in Q2 2022. REC-4881 received Fast Track designation for familial adenomatous polyposis (FAP), with a Phase 2 trial set for Q3 2022. Financially, Q1 2022 revenues reached $5.3 million, up from $2.6 million year-over-year, although R&D expenses rose to $32.4 million, contributing to a net loss of $56.0 million.

Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company, has announced its participation in the Bank of America 2022 Healthcare Conference, taking place from May 10 to May 13, 2022. This event will showcase Recursion's innovative approach to drug discovery through its Recursion Operating System, which integrates advanced technologies and vast datasets. Recursion aims to transform medicine by leveraging machine learning and running millions of experiments weekly. Webcasts will be available on the company's investor website.

Recursion (NASDAQ: RXRX) has received FDA Fast Track designation for its drug candidate REC-4881, aimed at treating familial adenomatous polyposis (FAP) in patients post-colectomy. This allosteric small molecule inhibitor targets MEK1 and MEK2, intended to reduce polyp burden and prevent progression to adenocarcinoma. The designation facilitates expedited drug review, enabling earlier access for patients upon approval. A Phase 2 trial for REC-4881 is set to enroll patients in Q3 2022, marking a significant step towards addressing the unmet needs in FAP treatment.

Recursion (NASDAQ: RXRX), a clinical-stage biotechnology firm, announced its participation in three upcoming investor conferences. These include the Piper Sandler AI/Machine Learning Conference on April 1, 2022, the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022, and the Berenberg Discover AI Seminar 2022 on April 26, 2022. The conferences are aimed at showcasing Recursion's advancements in drug discovery, leveraging its extensive biological and chemical datasets. Interested parties can access live webcasts via the investor section of Recursion's website.

Altitude Lab has announced that its inaugural cohort of startups has successfully raised $54 million in seed funding, marking the largest seed financing for life science startups in Utah's history. This incubation initiative, founded in partnership with Recursion and the University of Utah's PIVOT Center, focuses on supporting early-stage healthcare startups. With six out of seven startups securing financing within 18 months, the program emphasizes collaboration with biopharma and health systems, fostering growth in Utah's BioHive ecosystem.

Recursion (NASDAQ: RXRX) announced significant growth and collaborations in its press release on March 23, 2022. The company partnered with Roche and Genentech to develop up to 40 novel medicines, with an upfront payment of $150 million. Recursion expanded its collaboration with Bayer to explore over a dozen fibrosis programs. Additionally, the company initiated its Phase 2 clinical trial for CCM and advanced various oncology therapeutics. Financially, Recursion reported a net loss of $64.9 million for Q4 2021, a significant increase from the previous year.